Loading...
By Kelly Young
Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, DFASAM
Aspirin may be similar to other anticoagulants in preventing venous thromboembolism (VTE) and death in patients undergoing knee arthroplasty, according to a retrospective study in JAMA Surgery.
Researchers analyzed the records of 42,000 patients who underwent unilateral knee arthroplasty in Michigan hospitals. Patients who began only aspirin in the 3-day perioperative window were compared with those who began a nonaspirin anticoagulant (e.g., warfarin, factor Xa inhibitors), both, or no pharmacoprophylaxis.
The primary outcome — a composite of first pulmonary embolism, deep vein thrombosis, or death in the 90 days post-surgery — occurred in 4.8% of patients taking no anticoagulants, 1.2% of those taking aspirin alone, 1.4% of patients taking other anticoagulants, and 1.3% of those taking both. After multivariable adjustment, aspirin was noninferior to other anticoagulants for the primary outcome and for bleeding risk.
Commentators conclude: "While this study adds to the ongoing list of retrospective studies supporting the use of aspirin in selected patients who had undergone [total knee arthroplasty], the story is far from over."
Comment
LINK(S):
JAMA Surgery article (Free abstract)
JAMA Surgery commentary (Subscription required)
Background: Physician's First Watch coverage of randomized trial of aspirin vs. rivaroxaban after knee arthroplasty (Free)